Join
Live feed
·
PRReleasevia Quantisnow
Kineta Inc. logo

Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1

ByQuantisnow·Wall Street's wire, on your screen.
KA· Kineta Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KA (Kineta Inc.) and more on Quantisnow.